Entrada Therapeutics, Inc. (TRDA) Share-based Payment Arrangement, Expense USD 2020 - 2024

Historical data

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Entrada Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from 2020 to 2024.
  • Entrada Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending March 31, 2024 was $3.73 M, a 35.5% increase year-over-year.
  • Entrada Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending March 31, 2024 was $14.1 M, a 29.8% increase year-over-year.
  • Entrada Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $13.1 M, a 32.5% increase from 2022.
  • Entrada Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $9.9 M, a 292% increase from 2021.
  • Entrada Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $2.53 M, a 677% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 $14.1 M $3.73 M +$978 K +35.5% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-07
Q4 2023 $13.1 M $3.84 M +$959 K +33.3% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-13
Q3 2023 $12.2 M $3.4 M +$689 K +25.5% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-07
Q2 2023 $11.5 M $3.12 M +$607 K +24.2% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-08
Q1 2023 $10.9 M $2.76 M +$961 K +53.6% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q4 2022 $9.9 M $2.88 M +$1.42 M +97.7% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-13
Q3 2022 $8.47 M $2.71 M +$2.13 M +368% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-07
Q2 2022 $6.34 M $2.51 M +$2.19 M +671% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 $4.16 M $1.79 M +$1.63 M +994% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-10
Q4 2021 $2.53 M $1.46 M Oct 1, 2021 Dec 31, 2021 10-K 2023-03-06
Q3 2021 $578 K +$503 K +671% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-07
Q2 2021 $326 K Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 $164 K Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q3 2020 $75 K Jul 1, 2020 Sep 30, 2020 10-Q 2021-12-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.